Key Highlights
- Hemab shares are trading down 3.04% at $38.04 versus a prior close of $39.23.
- The third quarter loss was $0.58 per share versus about $0.52 expected.
- Cash was $430.2 million, funding operations into 2029.
- The Phase 3 SOLARA trial in Glanzmann thrombasthenia has started.
- Updated data are due at the ASH meeting on December 14.
Hemab Therapeutics (NASDAQ:COAG) is trading down 3.04% at $38.04 after a wider third quarter loss that missed estimates. The stock fell 9.44% on Tuesday to $38.77 after reaching $44.15 earlier that session.
Quarter Results
The net loss was $27.3 million, or $0.58 per share, against about $0.52 expected. R&D expense rose to $24.6 million from $14.6 million, and G&A rose to $5.1 million from $2.5 million. Cash and marketable securities were $430.2 million versus $457.5 million at June 30, and management continues to expect that to fund operations into 2029.
SOLARA Trial
The pivotal Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia is an open-label, single-arm study of about 75 patients using once-weekly subcutaneous dosing at 0.2 mg/kg, with a 24-week run-in, 48 weeks of treatment and a comparison within each patient. First participants enter the run-in before year-end. The FDA recommended considering a randomized trial but acknowledged feasibility concerns, and management called the Regulatory Risk very low.
Clinical Data
Phase 2 extension data in 34 participants showed a 62% reduction in mean high-intensity annualized treated bleed rate, and about 80% in the low-dose weekly cohort. There were no grade 3 or higher related adverse events, though three participants had grade 2 thromboembolic events. Early Factor VII deficiency data showed prothrombin time shortened by more than 50% in both participants dosed.
Von Willebrand Program
HMB-002 in von Willebrand disease showed peak increases of about 2.5-fold in VWF and Factor VIII against a 1.5-fold target, and eight of nine evaluable patients had zero treated bleeds in 28 days.
Analyst View
LifeSci initiated at Outperform with a $65 target, and JPMorgan holds Overweight with a $70 target. All three analysts are bullish.
Trial Design and Data Decide the Next Move
Shares are under pressure because of the single-arm design the FDA questioned. Investors will watch updated data at ASH, first patient entry into SOLARA and any further FDA feedback on the trial design.
The December 14 ASH presentation is the next marker.






Please wait processing your request...